Author(s)
Egocheaga I1, Games JM2, Barrios V3, Martinez I4, Mostaza JM5, Gomez Cerezo J6, Castellanos M7, Campuzano R8, Morant Talamante N9, Rodriguez Barrios JM9, Sicras-Mainar A10, Pérez Román I11, Parrondo García FJ12, Pallares V13
1Clinic Centre Isla de Oza, Madrid, Spain, 2Son Llazer University Hospital, Palma de Mallorca, Spain, 3Ramon Cajal University Hospital, Madrid, M, Spain, 4Son Spases University Hospital, Palma de Mallorca, Spain, 5La Paz University Hospital, Madrid, Spain, 6Infanta Sofia University Hospital, Madrid, Spain, 7A Coruña University Hospital & Biomedical Research institute, A Coruña, Spain, 8Alcorcón Foundation University Hospital, Alcorcón, Spain, 9Novartis Spain, Barcelona, M, Spain, 10Atrys Health, Badalona. Barcelona, B, Spain, 11Atrys Health, Madrid, M, Spain, 12Novartis Spain, Coslada, M, Spain, 13Unión de Mutuas, Castellón, Spain
BACKGROUND: Peripheral arterial disease (PAD) is a common manifestation of atherosclerosis, a cause of morbidity and mortality in developed countries and entails a high resource consumption and costs for health systems. These patients have an increased risk of suffering a new event with the consequent additional resource consumption and an increased follow-up cost. Despite this higher risk, PAD often goes unrecognized because symptoms are confused with other medical problems as musculoskeletal disorders, diabetic neuropathy, sciatica or venous disease. Although atherosclerotic risk factors as LDL-c were prevalent in these patients, they are often receiving suboptimal lipid-lowering treatments. OBJECTIVES:
Estimate the average annual cost per patient with a new diagnosis or new acute episode of PAD in patients with atherosclerotic cardiovascular disease in Spain.
METHODS:
A retrospective observational study of the electronic medical records of patients from the BIG-PAC® database (patients from 7 integrated areas of 7 Spanish Regions; n=1.8 million) was carried out. Patients with a new/recurrent PAD episode between 1/1/2017 and 12/31/2018 were included. Direct healthcare costs (DHCC) were calculated from the consumption of resources during follow-up (two years from diagnosis) and the mean of the Regions official published tariff. The indirect non-health costs (INHCC) associated with the loss of productivity were determined. All costs were updated to €2021.
RESULTS:
A total of 6,054 patients with PAD were detected in the recruitment period. During follow-up, 1,614 patients (26,6%) suffered a new cardiovascular event and 618 (10,2%) died. The mean cost per patient in the first year were €9,082 (DHCC) and €2,663 (INHCC) and €8,098 (DHCC) and €2,105 (INHCC) in the second year.
CONCLUSIONS:
Patients with PAD have a high mortality and represent a considerable social and healthcare cost. Developing preventive programs and controlling cardiovascular risk factors could help reduce mortality and cost for the Spanish National Health System.
Conference/Value in Health Info
2022-11, ISPOR Europe 2022, Vienna, Austria
Value in Health, Volume 25, Issue 12S (December 2022)
Code
EE636
Topic
Economic Evaluation
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)